Combination of GT90001 and nivolumab in patients with advanced hepatocellular carcinoma: a multicenter, single-arm, phase 1b/2 study

BACKGROUND: GT90001 (also known as PF-03446962) is an anti-ALK-1 monoclonal antibody and has shown activity in hepatocellular carcinoma (HCC). This phase 1b/2 study was designed to determine the recommended phase 2 dose (RP2D) of GT90001 plus nivolumab, and assess the safety and anti-tumor activity...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Chiun, Chang, Yi-Fang, Yen, Chia-Jui, Xu, Yu-Wei, Dong, Min, Tong, You-Zhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10588186/
https://www.ncbi.nlm.nih.gov/pubmed/37858184
http://dx.doi.org/10.1186/s12916-023-03098-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10588186/
https://www.ncbi.nlm.nih.gov/pubmed/37858184
http://dx.doi.org/10.1186/s12916-023-03098-w

Ejemplares similares